Osf Heart Of Mary Medical Center
- Type
- Teaching hospital
- Where
- Urbana, IL
- Medicare CCN
- 140113
- Received
- $1,184,435 in 246 records, 2025 ($131,407 general, $1,053,027 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 19 | $131,407 |
| 2025 | Research payment | 227 | $1,053,027 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| UCB SA | 2 | $391,817 | 2025 |
| Alkermes, Inc. | 152 | $242,378 | 2025 |
| ABBVIE INC. | 25 | $149,768 | 2025 |
| Regeneron Pharmaceuticals, Inc. | 1 | $92,540 | 2025 |
| Ardelyx, Inc. | 20 | $54,973 | 2025 |
| SANOFI US SERVICES INC. | 12 | $53,953 | 2025 |
| E.R. Squibb & Sons, L.L.C. | 1 | $47,575 | 2025 |
| Davol Inc. | 1 | $32,234 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $21,000 | 2025 |
| Vifor Pharma, Inc. | 2 | $19,015 | 2025 |
| Vifor (International) Ltd. | 1 | $19,000 | 2025 |
| Penumbra, Inc. | 1 | $13,700 | 2025 |
| OCCLUTECH US LLC | 1 | $13,059 | 2025 |
| GENZYME CORPORATION | 2 | $9,720 | 2025 |
| Siemens Medical Solutions USA, Inc. | 4 | $4,064 | 2025 |
| Smith+Nephew, Inc. | 1 | $3,000 | 2025 |
| Organogenesis Inc. | 1 | $3,000 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $3,000 | 2025 |
| Linde Gas & Equipment Inc. | 6 | $2,772 | 2025 |
| Stryker Corporation | 2 | $2,756 | 2025 |
| Biogen, Inc. | 1 | $2,000 | 2025 |
| Surmodics, Inc. | 2 | $1,625 | 2025 |
| Novo Nordisk Inc | 1 | $650 | 2025 |
| Cochlear Americas | 1 | $463 | 2025 |
| Haemonetics Corporation | 1 | $225 | 2025 |
| AstraZeneca UK Limited | 1 | $142 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 227 | $1,053,027 |
| Grant | 3 | $109,540 |
| Space rental or facility fees (teaching hospital only) | 13 | $18,647 |
| Debt forgiveness | 2 | $3,035 |
| Long term medical supply or device loan | 1 | $184 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Stryker Corporation | $2,572 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | ABBVIE INC. | $303 | Research payment | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | A Phase 3 Multicenter Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Upadacitinib with Open-Label Induction | 2025 |
| 2025-12-31 | Stryker Corporation | $184 | Long term medical supply or device loan | In-kind items and services | LIFEPAK 20 and LIFEPAK 20e defibrillator/monitors Device, EMS | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $70 | Research payment | In-kind items and services | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-10 | Alkermes, Inc. | $574 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-12-10 | Alkermes, Inc. | $500 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-12-05 | Alkermes, Inc. | $500 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-12-04 | AstraZeneca UK Limited | $142 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | An Observational Multi-center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobili | 2025 |
| 2025-12-04 | Alkermes, Inc. | $38 | Research payment | In-kind items and services | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-12-04 | Alkermes, Inc. | $27 | Research payment | In-kind items and services | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-12-02 | ABBVIE INC. | $845 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric | 2025 |
| 2025-12-01 | Alkermes, Inc. | $574 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-11-24 | SANOFI US SERVICES INC. | $750 | Research payment | Cash or cash equivalent | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 | |
| 2025-11-19 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-11-10 | Alkermes, Inc. | $12,200 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-11-10 | Alkermes, Inc. | $2,820 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-11-10 | Alkermes, Inc. | $2,500 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-11-10 | Alkermes, Inc. | $2,100 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-11-10 | Alkermes, Inc. | $2,000 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-11-10 | Alkermes, Inc. | $441 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-11-10 | Alkermes, Inc. | $441 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-11-10 | Alkermes, Inc. | $200 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-11-08 | Linde Gas & Equipment Inc. | $594 | Space rental or facility fees (teaching hospital only) | In-kind items and services | LGEREG081 Device, RESPIRATORY | 2025 | |
| 2025-11-07 | Penumbra, Inc. | $13,700 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIDE II | 2025 |
| 2025-11-05 | Alkermes, Inc. | $4,300 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-10-30 | ABBVIE INC. | $650 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric | 2025 |
| 2025-10-30 | Linde Gas & Equipment Inc. | $594 | Space rental or facility fees (teaching hospital only) | In-kind items and services | LGEREG081 Device, RESPIRATORY | 2025 | |
| 2025-10-30 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2025 | |
| 2025-10-25 | Novo Nordisk Inc | $650 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-10-20 | SANOFI US SERVICES INC. | $4,856 | Research payment | Cash or cash equivalent | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 | |
| 2025-10-20 | Ardelyx, Inc. | $750 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS | 2025 |
| 2025-10-20 | Ardelyx, Inc. | $750 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C | 2025 |
| 2025-10-17 | Vifor Pharma, Inc. | $15 | Research payment | Cash or cash equivalent | RLY5016-208P | 2025 | |
| 2025-10-08 | Alkermes, Inc. | $4,475 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-10-08 | Alkermes, Inc. | $4,475 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-10-08 | Alkermes, Inc. | $898 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-10-08 | Alkermes, Inc. | $433 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-10-02 | Ardelyx, Inc. | $16,000 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old | 2025 |
| 2025-10-02 | Ardelyx, Inc. | $3,150 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS | 2025 |
| 2025-10-02 | Ardelyx, Inc. | $2,320 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C | 2025 |
| 2025-10-02 | Ardelyx, Inc. | $750 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C | 2025 |
| 2025-10-02 | Ardelyx, Inc. | $750 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS | 2025 |
| 2025-09-30 | ABBVIE INC. | $585 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric | 2025 |
| 2025-09-26 | ABBVIE INC. | $3,002 | Research payment | Cash or cash equivalent | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | 2025 | |
| 2025-09-24 | Vifor (International) Ltd. | $19,000 | Research payment | Cash or cash equivalent | RLY5016-208P | 2025 | |
| 2025-09-24 | Vifor Pharma, Inc. | $19,000 | Research payment | Cash or cash equivalent | RLY5016-208P | 2025 | |
| 2025-09-24 | Surmodics, Inc. | $125 | Research payment | Cash or cash equivalent | PROWL Registry Device, Pounce Thrombectomy System Retrospective Registry | Pounce Thrombectomy System Retrospective Registry (PROWL) | 2025 |
| 2025-09-17 | Alkermes, Inc. | $7 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-09-15 | GENZYME CORPORATION | $7,270 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2025 | |
| 2025-09-09 | Siemens Medical Solutions USA, Inc. | $1,632 | Research payment | Cash or cash equivalent | ProBeam Proton Therapy System Device, Oncology | FLASH Radiotherapy for the treatment of symptomatic bone metastases in the thorax. | 2025 |
| 2025-09-08 | Alkermes, Inc. | $12,200 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-09-08 | Alkermes, Inc. | $4,475 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-09-08 | Alkermes, Inc. | $2,500 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-09-08 | Alkermes, Inc. | $2,100 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-09-08 | Alkermes, Inc. | $2,000 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-09-08 | Alkermes, Inc. | $898 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-09-08 | Alkermes, Inc. | $433 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-09-08 | SANOFI US SERVICES INC. | $207 | Research payment | Cash or cash equivalent | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 | |
| 2025-09-08 | Alkermes, Inc. | $200 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-09-04 | Biogen, Inc. | $2,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-09-04 | UCB SA | $1,228 | Research payment | In-kind items and services | Rystiggo Drug, Neurology | A randomized, double-blind, placebo-controlled, multicenter, phase 3, pivotal study with an open-lable extension period | 2025 |
| 2025-09-03 | ABBVIE INC. | $16,875 | Research payment | Cash or cash equivalent | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | 2025 | |
| 2025-09-03 | Alkermes, Inc. | $4,042 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-09-03 | Alkermes, Inc. | $172 | Research payment | In-kind items and services | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-09-03 | Alkermes, Inc. | $131 | Research payment | In-kind items and services | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-09-03 | Alkermes, Inc. | $71 | Research payment | In-kind items and services | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-09-03 | Alkermes, Inc. | $51 | Research payment | In-kind items and services | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-09-02 | ABBVIE INC. | $8,294 | Research payment | Cash or cash equivalent | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | 2025 | |
| 2025-09-02 | ABBVIE INC. | $5,624 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric | 2025 |
| 2025-08-28 | ABBVIE INC. | $27,845 | Research payment | Cash or cash equivalent | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | 2025 | |
| 2025-08-28 | ABBVIE INC. | $574 | Research payment | Cash or cash equivalent | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | 2025 | |
| 2025-08-26 | ABBVIE INC. | $715 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric | 2025 |
| 2025-08-25 | Ardelyx, Inc. | $1,820 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C | 2025 |
| 2025-08-20 | Alkermes, Inc. | $1,000 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-08-19 | Takeda Pharmaceuticals U.S.A., Inc. | $15,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-08-18 | Alkermes, Inc. | $500 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-08-13 | Alkermes, Inc. | $70 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-08-11 | SANOFI US SERVICES INC. | $9,200 | Research payment | Cash or cash equivalent | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 | |
| 2025-08-11 | SANOFI US SERVICES INC. | $3,000 | Research payment | Cash or cash equivalent | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 | |
| 2025-08-11 | Alkermes, Inc. | $2,878 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-08-06 | ABBVIE INC. | $6,531 | Research payment | Cash or cash equivalent | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | 2025 | |
| 2025-08-06 | Alkermes, Inc. | $2,651 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-08-06 | Alkermes, Inc. | $1,754 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-08-06 | Alkermes, Inc. | $441 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-07-31 | ABBVIE INC. | $14,041 | Research payment | Cash or cash equivalent | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | 2025 | |
| 2025-07-29 | Ardelyx, Inc. | $1,537 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C | 2025 |
| 2025-07-29 | Ardelyx, Inc. | $500 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old | 2025 |
| 2025-07-28 | Alkermes, Inc. | $3,880 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-07-25 | Alkermes, Inc. | $68 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-07-25 | Alkermes, Inc. | $34 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-07-21 | Alkermes, Inc. | $1,196 | Research payment | In-kind items and services | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-07-17 | Alkermes, Inc. | $650 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-07-10 | ABBVIE INC. | $82 | Research payment | Cash or cash equivalent | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | 2025 | |
| 2025-07-09 | Surmodics, Inc. | $1,500 | Research payment | Cash or cash equivalent | PROWL Registry Device, Pounce Thrombectomy System Retrospective Registry | Pounce Thrombectomy System Retrospective Registry (PROWL) | 2025 |
| 2025-07-08 | ABBVIE INC. | $9,732 | Research payment | Cash or cash equivalent | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | 2025 | |
| 2025-07-07 | Alkermes, Inc. | $4,042 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-07-07 | Alkermes, Inc. | $3,294 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-07-07 | Alkermes, Inc. | $136 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-07-07 | Alkermes, Inc. | $90 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-07-07 | Alkermes, Inc. | $68 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-07-07 | Alkermes, Inc. | $52 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-07-02 | ABBVIE INC. | $12,749 | Research payment | Cash or cash equivalent | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | 2025 | |
| 2025-07-02 | SANOFI US SERVICES INC. | $4,821 | Research payment | Cash or cash equivalent | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 | |
| 2025-07-02 | ABBVIE INC. | $390 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric | 2025 |
| 2025-07-01 | Ardelyx, Inc. | $8,000 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C | 2025 |
| 2025-06-30 | Haemonetics Corporation | $225 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TEG6S HEMOSTASIS SYSTEM Device, DEVICES | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $282 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $231 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $200 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $192 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $162 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $154 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $127 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $111 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $109 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $74 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $74 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $74 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $68 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $68 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $51 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $50 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $47 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $37 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $34 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $34 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $34 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $33 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $32 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $27 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $27 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $25 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $25 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $25 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $16 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $15 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $12 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $12 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $8 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $8 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $5 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $4 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $2 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $1 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $1 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-18 | Alkermes, Inc. | $1 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-16 | Siemens Medical Solutions USA, Inc. | $1,500 | Research payment | Cash or cash equivalent | Eclipse Treatment Planning System for External Beam Radiation Therapy Device, Oncology | FLASH Radiotherapy for the treatment of symptomatic bone metastases in the thorax. | 2025 |
| 2025-06-11 | Alkermes, Inc. | $8,402 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-11 | Alkermes, Inc. | $6,399 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-11 | Alkermes, Inc. | $3,286 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-11 | Alkermes, Inc. | $979 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-11 | Alkermes, Inc. | $433 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-06-05 | Smith+Nephew, Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | STRAVIX Biological, Extremities & Limb Restoration | 2025 | |
| 2025-06-04 | Alkermes, Inc. | $1,196 | Research payment | In-kind items and services | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-05-29 | Alkermes, Inc. | $1,045 | Research payment | In-kind items and services | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-05-28 | Ardelyx, Inc. | $2,110 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS | 2025 |
| 2025-05-28 | Ardelyx, Inc. | $1,395 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C | 2025 |
| 2025-05-16 | Alkermes, Inc. | $1,062 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-05-16 | Alkermes, Inc. | $1,062 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-05-12 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-05-09 | ABBVIE INC. | $1,495 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric | 2025 |
| 2025-05-07 | Alkermes, Inc. | $2,878 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-05-07 | Alkermes, Inc. | $2,534 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-05-07 | Alkermes, Inc. | $898 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-05-07 | Alkermes, Inc. | $433 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-29 | Ardelyx, Inc. | $500 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | Phase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old | 2025 |
| 2025-04-28 | SANOFI US SERVICES INC. | $1,955 | Research payment | Cash or cash equivalent | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 | |
| 2025-04-26 | Organogenesis Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PURAPLY WOUND MATRIX Device, WOUND CARE | 2025 | |
| 2025-04-25 | Siemens Medical Solutions USA, Inc. | $500 | Research payment | Cash or cash equivalent | ProBeam Proton Therapy System Device, Oncology | FLASH Radiotherapy for the treatment of symptomatic bone metastases in the thorax. | 2025 |
| 2025-04-25 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, RESPIRATORY | 2025 | |
| 2025-04-25 | Alkermes, Inc. | $136 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-22 | Ardelyx, Inc. | $1,229 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS | 2025 |
| 2025-04-21 | Alkermes, Inc. | $12,200 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-21 | Alkermes, Inc. | $7,669 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-21 | Alkermes, Inc. | $6,175 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-21 | Alkermes, Inc. | $5,308 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-21 | Alkermes, Inc. | $2,942 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-21 | Alkermes, Inc. | $2,534 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-21 | Alkermes, Inc. | $2,500 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-21 | Alkermes, Inc. | $2,100 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-21 | Alkermes, Inc. | $2,000 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-21 | Alkermes, Inc. | $898 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-21 | Alkermes, Inc. | $433 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-21 | Alkermes, Inc. | $200 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-16 | Alkermes, Inc. | $12,200 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-16 | Alkermes, Inc. | $200 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-14 | SANOFI US SERVICES INC. | $1,500 | Research payment | Cash or cash equivalent | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 | |
| 2025-04-08 | Ardelyx, Inc. | $5,488 | Research payment | Cash or cash equivalent | IBSRELA Drug, GASTROENTEROLOGY | TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS | 2025 |
| 2025-04-07 | Alkermes, Inc. | $2,500 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-07 | Alkermes, Inc. | $2,100 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-07 | Alkermes, Inc. | $2,000 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-03 | Alkermes, Inc. | $259 | Research payment | In-kind items and services | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-04-03 | Alkermes, Inc. | $119 | Research payment | In-kind items and services | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-04-03 | Alkermes, Inc. | $113 | Research payment | In-kind items and services | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-04-03 | Alkermes, Inc. | $82 | Research payment | In-kind items and services | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-04-03 | Alkermes, Inc. | $77 | Research payment | In-kind items and services | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-04-03 | Alkermes, Inc. | $77 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-04-03 | Alkermes, Inc. | $56 | Research payment | In-kind items and services | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-04-03 | Alkermes, Inc. | $52 | Research payment | In-kind items and services | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-04-03 | Alkermes, Inc. | $25 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 |
The latest 200 records of 246.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Urbana, IL, county Champaign County, IL, state Illinois; placed by its city name.
| Measure | Place (city or town) Urbana, IL | County Champaign County, IL | State Illinois |
|---|---|---|---|
| Population B01003 | 39,341 | 208,741 | 12,694,798 |
| Population, 2020 census P1 | 38,336 | 205,865 | 12,812,508 |
| Median age B01002 | 26.1 | 30.7 | 39.0 |
| Under 18 B01001 | 13.2% | 19.1% | 21.8% |
| 65 and over B01001 | 11.5% | 13.9% | 17.0% |
| Households B11001 | 16,856 | 85,472 | 5,036,449 |
| Foreign born B05002 | 21.2% | 14.2% | 14.7% |
| Median household income B19013 | $45,346 | $63,683 | $83,390 |
| Median family income B19113 | $86,209 | $100,396 | $106,018 |
| Per capita income B19301 | $32,592 | $38,439 | $46,406 |
| Poverty rate B17001 | 28.0% | 19.1% | 11.8% |
| Unemployment rate B23025 | 4.7% | 4.3% | 5.8% |
| Civilian labor force B23025 | 20,316 | 104,876 | 6,652,134 |
| Mean commute (minutes) B08013 | 14.2 | 16.9 | 27.8 |
| Bachelor's degree or higher B15003 | 56.7% | 46.2% | 37.8% |
| Housing units B25001 | 19,228 | 95,115 | 5,457,452 |
| Owner-occupied B25003 | 37.3% | 54.0% | 67.1% |
| Renters B25003 | 62.7% | 46.0% | 32.9% |
| Median home value B25077 | $184,900 | $211,500 | $263,300 |
| Median gross rent B25064 | $972 | $1,051 | $1,274 |
| White, not Hispanic B03002 | 52.9% | 62.4% | 58.1% |
| Black B03002 | 18.7% | 13.4% | 13.3% |
| Hispanic or Latino B03002 | 10.1% | 8.3% | 18.8% |
| Asian B03002 | 14.2% | 11.4% | 5.9% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Urbana, IL.
Comments